

| | | | | | | | |
|--|-----|-----------------|----------|--|-------|------------------------------|-------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | | | | ATTY DOCKET NO. 11068-052-999 (Formerly 65166/JPW) | | APPLICATION NO 09/874,475 | |
| | | | | APPLICANT Petrooulos et al. | | | |
| | | | | FILING DATE 6/04/01 | | GROUP 1648 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINE R INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| W | A01 | 5,837,464 | 11/17/98 | Capon et al. | — | — | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---|-----|-----------------|---------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| W | A02 | WO 97/27319 | 1/29/97 | PCT | — | — | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|---|-----|---|
| W | A03 | Alkhatib <i>et al.</i> , 1996, "CC CKR5: A Rantes, MIP-1alpha, MIP-1 Beta Receptor as a Fusion Cofactor for Macrophage-tropic Hiv-1," <i>Science</i> , 272:1955-58. |
| | A04 | Allaway <i>et al.</i> , 1993, "Synergistic Inhibition of HIV-1 Envelope-Mediated Cell Fusion by CD4-based Molecules in Combination with Antibodies to Gp120 or Gp41," <i>Aids Res. Hum. Retroviruses</i> , 9:581-87. |
| | A05 | Baba <i>et al.</i> , 1999, "A Small-molecule, Nonpeptide CCR5 Antagonist with Highly Potent and Selective Anti-hiv-1 Activity," <i>Proc. Natl. Acad. Sci. USA</i> , 96:5698-03. |
| | A06 | Barnes, W.M., 1994, "PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates," <i>Proc. Natl. Acad. Sci. USA</i> 91, 2216-20. |
| | A07 | Baxter <i>et al.</i> , 1999, "A Pilot Study of the Short-term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (Gart) in Patients Failing Antiretroviral Therapy," <u>Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.</u> |
| | A08 | Bernard and Couturier, 1992, "Cell Killing by the F Plasmid CcdB protein Involves Poisoning of DNA topoisomerase II Complexes," <i>J. Mol. Bio.</i> 226:735-45. |
| | A09 | Bernard <i>et al.</i> , 1993, "The F Plasmid CcdB protein Induces Efficient ATP-dependent Dna Cleavage by Gyrase," <i>J. Mol. Biol.</i> 23:534-41. |
| | A10 | Bleul <i>et al.</i> , 1996, "The Lymphocyte Chemoattractant Sdf-1 Is a Ligand for Lestr/fusin and Blocks Hiv-1 Entry," <i>Nature</i> 382:829-33. |
| | A11 | Bridger <i>et al.</i> , 1999, "Synthesis and Structure-activity Relationships of Phenylenebis(methylene)-linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4," <i>J. Med. Chem.</i> 42:3971-81. |
| | A12 | Coffin, 1995, "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy," <i>Science</i> 267:483-489. |
| | A13 | DHHS (Department of Health and Human Services), 2000, Henry Kaiser Family Foundation: "Guidelines for the Use of Antiretrovirals Agents in HIV-infected Adults and Adolescents." |
| | A14 | Dorn <i>et al.</i> , 2001, "Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 1: Discovery and Initial Structure-Activity Relationships for 1-Amino-2-phenyl-4-(piperidin-1-yl) butanes," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:259-64. |
| | A15 | Finke <i>et al.</i> , 2001, "Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 4: Synthesis and Structure-Activity Relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl) butanes," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:2475-79. |
| | A16 | Gerdes <i>et al.</i> , 1990, "The Hok Killer Gene Family in Gram-negative Bacteria," <i>The New Biologist</i> : 2:946-56. |
| | A17 | Hertogs <i>et al.</i> , 1998, "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs," <i>Antimicrob. Agents Chemother.</i> 42:269-76. |
| | A18 | Hwang <i>et al.</i> , 1997, "A Conditional Self-inactivating Retrovirus Vector That Uses a Tetracycline-responsive Expression System," <i>J. Virol.</i> 71: 7128-31. |
| | A19 | Japour <i>et al.</i> , 1993, "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrob. Agents Chemother.</i> |

| | | |
|----|-----|---|
| | | 37:1095-01. |
| CW | A20 | Judice <i>et al.</i> , 1997, "Inhibition HIV Type 1 Infectivity by Constrained Alpha-helical Peptides: Implications for the Viral Fusion Mechanism," <i>Proc. Natl. Acad. Sci. USA</i> 94:13426-30. |
| | A21 | Kilby <i>et al.</i> , 1998, "Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of Gp41-mediated Virus Entry," <i>Nat Med.</i> 4:1302-07. |
| | A22 | Mascola <i>et al.</i> , 2000, "HIV-1 Entry at the Mucosal Surface: Role of Antibodies in Protection," <i>AIDS</i> , 14 (suppl 3): S167-174. |
| | A23 | Mascola <i>et al.</i> , 2000, "Protection of Macaques Against Vaginal Transmission of a Pathogenic HIV-1/siv Chimeric Virus by Passive Infusion of Neutralizing Antibodies," <i>Nature Med.</i> 6:207-10. |
| | A24 | Miyoshi <i>et al.</i> , 1998, "Development of a Self-inactivating Lentivirus Vector," <i>J. Virol.</i> 72:8150-57. |
| | A25 | Naviaux <i>et al.</i> , 1996, "The Pcl Vector System: Rapid production of Helper-free, High-titer, Recombinant Retroviruses," <i>J. Virol.</i> 70: 5701-05. |
| | A26 | Petropoulos <i>et al.</i> , 2000, "A Novel Phenotypic Drug Susceptibility Assay for HIV-1," <i>Antimicrob. Agents & Chem.</i> 44:920-28. |
| | A27 | Piketty <i>et al.</i> , 1999, "Efficacy of a Five-drug Combination Including Ritonavir, Saquinavir and Efavirenz in Patients Who Failed on a Conventional Triple-drug Regimen: Phenotypic Resistance to protease Inhibitors predicts Outcome of Therapy," <i>Aids</i> : 13:f71-f77. |
| | A28 | Porter <i>et al.</i> , 1998, "Cationic Liposomes Enhance the Rate of Transduction by a Recombinant Retroviral Vector in Vitro and in Vivo," <i>J. Virol.</i> 72:4832-40. |
| | A29 | Reimann <i>et al.</i> , 1995, "In Vivo Administration of CD4-specific Monoclonal Antibody: Effect on provirus Load in Rhesus Monkeys Chronically Infected with the Simian Immunodeficiency Virus of Macaques," <i>Aids Res. Hum. Retroviruses</i> 11:517-25. |
| | A30 | Rimsky <i>et al.</i> , 1998, "Determinants of Human Immunodeficiency Virus Type 1 Resistance to Gp41-derived Inhibitory Peptides," <i>J. Virol.</i> 72:986-93. |
| | A31 | Rodriguez-Rosado <i>et al.</i> , 1999, "Introduction of HIV Drug-resistance Testing in Clinical Practice," <i>Aids</i> 13:1007-14. |
| | A32 | Sarkar <i>et al.</i> , 1990, "The "Megaprimer" Method of Site-Directed Mutagenesis," <i>Biotechniques</i> 8:404-07. |
| | A33 | Sarkat <i>et al.</i> , 1990, "Shedding Light on PCR contamination," <i>Nature</i> 343:27. |
| | A34 | Schinazi <i>et al.</i> , 1999, "Mutations in Retroviral Genes Associated with Drug Resistance," <i>Intl. Antiviral News</i> : 7:46-49. |
| | A35 | Shi <i>et al.</i> , 1997, "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to Reverse Transcriptase Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 41:2781-85 |
| | A36 | Wild <i>et al.</i> , 1992, "A Synthetic Peptide Inhibitor of HIV Replication: Correlation Between Solution Structure and Viral Inhibition," <i>Proc. Natl. Acad. Sci. USA</i> 89:10537-41. |
| | A37 | http://hiv-web.lanl.gov/content/index Last accessed on May 1, 2003. |
| | A38 | Zennou <i>et al.</i> , 1998, "Loss of Viral Fitness Associated with Multiple Gag and Gag-pol processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors in vivo," <i>J. Virol.</i> 72:3300-06. |
| ↓ | A39 | Ziermann <i>et al.</i> , 2000, "A Mutation in HIV-1 Protease, N88s, That Causes in Vitro Hypersensitivity to Amprenavir," <i>J. Virol.</i> 74:4414-19. |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.